Prostate Cancer Disparities in Hispanics Using the National Cancer Database

Pino, Matthew Del; Abern, Michael R.; Moreira, Daniel

doi:10.1016/j.urology.2022.02.025

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second major issue is how much prostate cancer incidence trends differed by race and ethnicity. Disparities in cancer incidence have been observed over the past few decades for prostate cancer and many other cancers ( 18 – 22 , 24 – 28 ). Numerous studies have consistently found substantial racial disparities in prostate cancer incidence with a higher rate in blacks and a lower rate in Asians and AIANs ( 1 – 3 , 18 , 19 , 27 – 32 ).…”

Section: Discussionmentioning

confidence: 99%

“…There are some limitations to be noted in this study. First, ethnic differences in cancer incidence among the subgroups of Hispanic men such as Mexican or Cuban Americans, or among the subgroups of Asian/Pacific Islanders such as Chinese, Korean, Japanese or Pilipino Americans have been reported ( 2 , 20 – 22 , 31 ), but these subgroup differences in prostate cancer incidence cannot be addressed because of no information on population denominators in SEER*Stats data. Second, place of birth and time of migration were reported to affect the cancer incidence rates by race and ethnicity ( 33 – 35 ), but because of lack of data for population denominators and prostate cancer cases by place of birth and time of migration, our study cannot address the prostate cancer incidence disparities by U.S.-born or foreign-born men or by the timing of migration for those men who immigrated from other countries.…”

Section: Discussionmentioning

confidence: 99%

“…Good news is that prostate cancer mortality has continued to decline ( 1 ). Although several studies examined racial disparities in prostate cancer incidence, tumor stage and mortality in recent years ( 18 – 22 ), they did not examine the prostate cancer incidence trend over time by race and ethnicity. Therefore, this study aimed to make some unique contributions to the existing literature: 1) to utilize the latest cancer registry data released in April 2023 to study the prostate cancer incidence trends from 2000 to 2020 in the United States by race and ethnicity, age and stage, including racial disparities in unknown tumor stage; 2) to explore racial differences in prostate cancer incidence change due to the impact of COVID-19 pandemic lockdown in 2020; and 3) to determine if there is any high-risk population that can be targeted for screening, prevention and intervention in order to decrease the prostate cancer occurrence and reduce the disparities.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Incidence trends in prostate cancer among men in the United States from 2000 to 2020 by race and ethnicity, age and tumor stage

Du,

Gao,

2023

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo explore whether prostate cancer incidence trends from 2000 to 2020 in the United States differed by race and ethnicity, age and tumor stage; to explore racial differences in prostate cancer incidence change due to the impact of COVID-19 pandemic lockdown in 2020; and to determine if there is any high-risk population that can be targeted for prevention.MethodsWe identified 1,098,349 men who were diagnosed with incident prostate cancer at age ≥20 in 2000-2020 in 17 registries of the Surveillance, Epidemiology, and End Results (SEER) program in the United States; of whom, 778,437 were non-Hispanic whites, 155,111 non-Hispanic blacks, 4,200 American Indians and Alaska Natives (AIAN), 55,267 non-Hispanic Asians/Pacific Islanders, and 105,334 Hispanics.ResultsAge-adjusted incidence rate of prostate cancer was the highest in blacks (302.6 cases per 100,000 men), followed by whites (186.6), Hispanics (153.2), AIAN (108.5), and Asians (104.9). Age-adjusted prostate cancer incidence rates dramatically decreased from 2000 to 2013 for all ethnic men. However, age-adjusted prostate cancer incidence rates increased from 2014 to 2020, in which the increasing incidence trend looked sharper in blacks and whites, flatter in Asians, and leveled in AIAN and Hispanics. Among men with local or regional stages across all years, prostate cancer incidence rate was significantly higher in blacks, but significantly lower in Hispanics, AIAN, and Asians as compared to whites. Among men in 2007-2013, the risk of distant stage prostate cancer was statistically significantly elevated in blacks (rate-ratio: 2.22, 95% CI: 2.06-2.38) and Hispanics (1.16, 1.06-1.25), not significantly different in AIAN (1.30, 0.92-1.76), but still significantly lower in Asians (0.73, 0.66-0.82) as compared to whites. There was a drop of prostate cancer incidence from 2019 to 2020 likely due to the impact of COVID-19 pandemic lockdown on the access to medical care in 2020. Overall prostate cancer incidence rate decreased by 40.4 cases per 100,000 population from 277.4 in 2019 to 237.0 in 2020 for blacks, 20.9 from 164.2 to 143.3 for whites, 16.8 from 124.8 to 108.0 for Hispanics, 14.9 from 101.7 to 86.8 for AIAN, and 12.6 from 88.4 to 75.8 for Asians.ConclusionThe decreasing trend of prostate cancer incidence from 2000 to 2013 was statistically significant for all ethnic men. There was an increasing prostate cancer incidence from 2014 to 2020. Age-adjusted incidence rate of prostate cancer was the highest in blacks, followed by whites, Hispanics, AIAN, and Asians, regardless of age groups, tumor stages, and time periods. There will also be a need to monitor and investigate the prostate cancer incidence trend during and after COVID-19 pandemic season.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence trends in prostate cancer among men in the United States from 2000 to 2020 by race and ethnicity, age and tumor stage

Du,

Gao,

2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Among the Hispanic community, Mexican men present a more aggressive disease with an advanced stage at diagnosis and mortality rates are higher compared to other Hispanic American and No-Hispanic White men [10]. The Latino population, characterized by genetic admixture from various ancestral populations [11], however, genetic alterations in Hispanic men with PRAD are less described than other ethnic groups [12].…”

Section: Introductionmentioning

confidence: 99%

Genomic Landscape of Early-Stage Prostate Adenocarcinoma in Mexican patients: An exploratory study

Cerrato-Izaguirre,

González-Ruíz,

Diaz-Chavez

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Health disparities have been highlighted among patient with prostate adenocarcinoma (PRAD) due to ethnicity. Mexican men present a more aggressive disease than other patients resulting in less favorable treatment outcome. We aimed to identify the mutational landscape which could help to reduce the health disparities among minority groups and generate the first genomics exploratory study of PRAD in Mexican patients. Methods Paraffin-embedded formalin-fixed tumoral tissue from 20 Mexican patients with early-stage PRAD treated at The Instituto Nacional de Cancerología, Mexico City from 2017–2019 were analyzed. Tumoral DNA was prepared for whole exome sequencing, the resulting files were mapped against h19 using BWA-MEM. Strelka2 and Lancet packages were used to identify single nucleotide variants (SNV) and insertions or deletions. FACETS was used to determine somatic copy number alterations (SCNA). Cancer Genome Interpreter web interface was used to determine the clinical relevance of variants. Results Patients were in an early clinical stage and had a mean age of 59.55 years (standard deviation [SD]: 7.1 years) with 90% of them having a Gleason Score of 7. Follow-up time was 48.50 months (SD: 32.77) with recurrences and progression in 30% and 15% of the patients, respectively. NUP98 (20%), CSMD3 (15%) and FAT1 (15%) were the genes most frequently affected by SNV; ARAF (75%) and ZNF419 (70%) were the most frequently affected by losses and gains SNCA’s. One quarter of the patients had mutations useful as biomarkers for the use of PARP inhibitors, they comprise mutations in BRCA, RAD54L and ATM. SBS05, DBS03 and ID08 were the most common mutational signatures present in this cohort. No associations with recurrence or progression were identified. Conclusions This study reveals the mutational landscape of early-stage prostate adenocarcinoma in men. Understanding mutational patterns and actionable mutations in early prostate cancer can inform personalized treatment approaches and reduce the underrepresentation in genomic cancer studies.

show abstract

Genomic landscape of early-stage prostate adenocarcinoma in Mexican patients: an exploratory study

Cerrato-Izaguirre,

González-Ruíz,

Diaz-Chavez

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background Health disparities have been highlighted among patient with prostate adenocarcinoma (PRAD) due to ethnicity. Mexican men present a more aggressive disease than other patients resulting in less favorable treatment outcome. We aimed to identify the mutational landscape which could help to reduce the health disparities among minority groups and generate the first genomics exploratory study of PRAD in Mexican patients. Methods Paraffin-embedded formalin-fixed tumoral tissue from 20 Mexican patients with early-stage PRAD treated at The Instituto Nacional de Cancerología, Mexico City from 2017 to 2019 were analyzed. Tumoral DNA was prepared for whole exome sequencing, the resulting files were mapped against h19 using BWA-MEM. Strelka2 and Lancet packages were used to identify single nucleotide variants (SNV) and insertions or deletions. FACETS was used to determine somatic copy number alterations (SCNA). Cancer Genome Interpreter web interface was used to determine the clinical relevance of variants. Results Patients were in an early clinical stage and had a mean age of 59.55 years (standard deviation [SD]: 7.1 years) with 90% of them having a Gleason Score of 7. Follow-up time was 48.50 months (SD: 32.77) with recurrences and progression in 30% and 15% of the patients, respectively. NUP98 (20%), CSMD3 (15%) and FAT1 (15%) were the genes most frequently affected by SNV; ARAF (75%) and ZNF419 (70%) were the most frequently affected by losses and gains SNCA’s. One quarter of the patients had mutations useful as biomarkers for the use of PARP inhibitors, they comprise mutations in BRCA, RAD54L and ATM. SBS05, DBS03 and ID08 were the most common mutational signatures present in this cohort. No associations with recurrence or progression were identified. Conclusions This pilot study reveals the mutational landscape of early-stage prostate adenocarcinoma in Mexican men, providing a first approach to understand the mutational patterns and actionable mutations in early prostate cancer can inform personalized treatment approaches and reduce the underrepresentation in genomic cancer studies.

show abstract

Prostate Cancer Disparities in Hispanics Using the National Cancer Database

Cited by 4 publications

References 24 publications

Incidence trends in prostate cancer among men in the United States from 2000 to 2020 by race and ethnicity, age and tumor stage

Incidence trends in prostate cancer among men in the United States from 2000 to 2020 by race and ethnicity, age and tumor stage

Genomic Landscape of Early-Stage Prostate Adenocarcinoma in Mexican patients: An exploratory study

Genomic landscape of early-stage prostate adenocarcinoma in Mexican patients: an exploratory study

Contact Info

Product

Resources

About